Estradiol Valerate

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women’s health, offering access to affordable treatment plans built specifically for women experiencing perimenopause and menopause. Starting today, women can work with a provider on the platform to access treatment plans tailored to their health history and personal preferences. There is a clear gap in health care access for women: women will spend an average of nine years in poor health, which is 25% more than men, and can impact their ability to be present at work, at home, and in their communities.1 Since its founding in 2018, Hers has been breaking down barriers to care and providing access to high-quality care and empowering support that meets women on their own terms. Today, Hers serves over half a million subscribers2 and is on track to surpass $1B of annual revenue in 2026.3 By entering menopause and perimenopause, the company will be able to reach more women with access to care built specifically for them. Around 1.3 million women in the US experience menopause each year,4 but only about 30% of OB/GYN residency programs provide formal menopause training.5 Women are often left to navigate symptoms, like mood changes, sleep problems, and dry skin and hair, on their own. Hers is using its scale to change that dynamic. “This isn’t just about medication – it’s about building and growing a platform that women can trust to access the care they need. Women have been navigating an outdated healthcare system that wasn’t designed for them for too long. Hers was built to serve every woman on her terms,” said Dr. Jessica Shepherd, Chief Medical Officer of Hers. “I’ve been an OB/GYN for more than 20 years, and I know that transforming the healthcare experience for women starts with increasing access to providers who are trained specifically in caring for women at every life stage. As one of the largest digital health platforms, we can help change the way women experience healthcare and thrive.” For eligible customers, personalized menopause and perimenopause treatment plans through Hers may include prescription medication in pill, patch, or cream forms.6 Treatments for eligible customers may include estradiol, a hormone naturally made in the body, to help alleviate symptoms of menopause like hot flashes and night sweats, and progesterone, which helps protect the uterine lining and improve sleep quality. Every customer’s care experience is directed by an independent licensed provider trained in perimenopause and menopause care, who can help adjust the plan over time to meet their patient’s needs. The company expects to introduce access to an expanded range of treatment options next year. For more information, visit forhers.com/menopause and forhers.com/perimenopause. Media Kit LINK About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com. Cautionary Note Regarding Forward-Looking Statements This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding our expectations regarding subscriber growth and customer adoption of the offerings in the menopause or perimenopause specialty, the revenue we anticipate to generate from this specialty, the expected timing of any revenue generation, the timing and market acceptance of any new products or offerings, the pricing of any new products or offerings, our market opportunity, the growth of this specialty, our ability to innovate on and expand the scope of our offerings and experiences, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, failure of offerings to perform as expected; limited market acceptance of new offerings; inability to achieve expected subscriber growth; failure to realize the revenue we anticipate to generate from these offerings; challenges in scaling provider capacity with relevant training; inability to expand treatment availability or add new treatment options; inability to obtain or maintain regulatory approvals; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; specific risks related to menopause-related therapies; competitive product launches; higher than anticipated launch or marketing costs; shifts in consumer spending or behavior; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of October 15, 2025. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication. We may include statements and information in this communication concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this communication, we have not independently verified any third-party information and such information is inherently imprecise. ____________________ 1https://www.mckinsey.com/mhi/our-insights/closing-the-womens-health-gap-a-1-trillion-dollar-opportunity-to-improve-lives-and-economies 2As of 6/30/2025. 3Projected by 12/31/2026. 4https://swhr.org/health_focus_area/menopause/ 5https://journals.lww.com/menopausejournal/abstract/2023/10000/needs_assessment_of_menopause_education_in_united.4.aspx 6Not available in all 50 states. Rx required. Perimenopause & Menopause by Hers is a holistic program that includes hormonal health support, educational resources, and access to prescription medications if a licensed provider determines they are medically appropriate for you. Hormone replacement therapies, such as estradiol tablets, progesterone, transdermal estradiol, and estradiol vaginal cream, are not approved or evaluated by the FDA for the prevention, diagnosis, or treatment of perimenopause but may be prescribed off-label at a healthcare provider’s discretion. See website for full details, important safety information, and restrictions, including online provider consultation requirements.

FRIDAY, Aug. 29, 2025 -- Earlier age at menopause is associated with lower scores on all cognitive domains, and menopausal hormone therapy (MHT) differentially affects cognition, according to a study published online Aug. 27 in Neurology . Tanvi A. Puri, from the University of British Columbia in Vancouver, Canada, and colleagues conducted a cross-sectional observational cohort study using baseline data from the Canadian Longitudinal Study of Aging. The associations of age at menopause and estradiol (E2)-based MHT by administration route were examined with performance in three cognitive domains in a cohort of 7,251 postmenopausal women. The researchers found that across all cognitive domains tested, earlier age at menopause was significantly associated with lower scores (β = 0.050, 0.047, 0.061, respectively, for episodic memory, prospective memory, and executive functions). For executive functions, only those with four or more children versus no children had lower performance in association with earlier age at menopause (β = 0.215); a greater effect size was seen among APOE4 ε4 carriers versus noncarriers (β = 0.070). Transdermal E2 was associated with higher episodic memory scores, and oral E2 was associated with higher prospective memory scores compared with never taking MHT. Executive functions were not affected by either administration route. "This study highlights that the type of estradiol therapy used may influence cognitive performance differently across various types of memory," coauthor Liisa A.M. Galea, Ph.D., also from the University of British Columbia, said in a statement. "Understanding these links could help inform more tailored approaches to maintaining brain health after menopause." Abstract/Full Text Editorial (subscription or payment may be required)